Bright Minds Biosciences Inc. Share Price
Equities
DRUG
CA10919W4056
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 102.39 CAD | -4.40% |
|
-8.99% | -7.28% |
| Capitalization | 1B 728M 627M 573M 547M 69.86B 1.02B 6.87B 2.66B 33.17B 2.73B 2.67B 116B | P/E ratio 2026 * |
-14.3x | P/E ratio 2027 * | -7.77x |
|---|---|---|---|---|---|
| Enterprise value | 1B 728M 627M 573M 547M 69.86B 1.02B 6.87B 2.66B 33.17B 2.73B 2.67B 116B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 29.8x |
| Free-Float |
88.45% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -4.40% | ||
| 1 week | -8.99% | ||
| Current month | -14.59% | ||
| 1 month | -14.14% | ||
| 3 months | -1.07% | ||
| 6 months | +25.96% | ||
| Current year | -7.28% |
| 1 week | 101.98 |  | 117.34 |
| 1 month | 101.98 | | 124.38 |
| Current year | 93.63 | | 170 |
| 1 year | 33.01 | | 170 |
| 3 years | 1.29 | | 170 |
| 5 years | 1.29 | | 170 |
| 10 years | 1.29 | | 170 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ian McDonald
CEO | Chief Executive Officer | 38 | 04/06/2020 |
Ryan Cheung
DFI | Director of Finance/CFO | 47 | 28/05/2020 |
| Chief Tech/Sci/R&D Officer | - | 06/01/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Jeremy Fryzuk
BRD | Director/Board Member | 40 | 28/09/2020 |
Nils Bottler
BRD | Director/Board Member | 38 | 28/09/2020 |
Ian McDonald
BRD | Director/Board Member | 38 | 30/05/2019 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.40% | -8.99% | +126.38% | +2,630.40% | 728M | |
| -1.01% | -2.82% | -18.17% | -19.32% | 41.67B | |
| -3.73% | -6.04% | +28.41% | +22.76% | 32.6B | |
| -2.55% | +2.71% | +268.39% | +468.32% | 30.97B | |
| -0.91% | -5.37% | +18.41% | -11.55% | 28.23B | |
| -3.23% | -4.84% | +27.50% | +22.65% | 26.41B | |
| -2.03% | +0.77% | - | - | 14.94B | |
| +6.21% | -2.39% | +176.35% | +4,385.95% | 14.13B | |
| -1.92% | -1.95% | +121.19% | +106.25% | 12.27B | |
| -0.20% | -0.10% | +5.63% | -1.89% | 12.12B | |
| Average | -1.38% | -2.55% | +83.79% | +844.84% | 21.41B | |
| Weighted average by Cap. | -1.52% | -2.20% | +69.63% | +401.21% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 33.61M 24.42M 21.01M 19.21M 18.33M 2.34B 34.16M 231M 89.2M 1.11B 91.65M 89.69M 3.88B |
| Net income | -68.25M -49.59M -42.68M -39.02M -37.23M -4.76B -69.38M -468M -181M -2.26B -186M -182M -7.87B | -149M -108M -93.18M -85.19M -81.28M -10.39B -151M -1.02B -396M -4.93B -406M -398M -17.18B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/05/26 | 102.39 $ | -4.40% | 2,419 |
| 14/05/26 | 107.10 $ | -7.89% | 1,922 |
| 13/05/26 | 116.28 $ | +3.24% | 167 |
| 12/05/26 | 112.63 $ | -3.63% | 1,788 |
| 11/05/26 | 116.87 $ | +3.88% | 1,501 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- DRUG Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition